Adjusting to change in healthcare: Learning from translational research
In this article, Blue Latitude Health's Head of Insight, Martine Leroy, explores how pharma could learn from translational research organisations in adapting their approach to the changing healthcare landscape.
Healthcare is undergoing a transformative change, which presents challenges to all players in the sector. Factors of change include evolving expectations and requirements from populations and governments, and newcomers to the field that are changing both supply and demand. Established healthcare players like pharma need to control and shape their emerging roles. In this respect, pharma needs to be more pro-active if it is to strengthen and enhance its role. Its efforts to date seem quite timid.
Translational research organisations are healthcare players who are adjusting their strategies in anticipation of change, thus turning challenges into opportunities. What if pharma learned how to adapt faster and more effectively from these organisations? Head of Insight Martine Leroy explores this ‘what if’ scenario, outlining the ways that pharma could learn from translational research organisations and improve their approach to the changing healthcare landscape.
Translational research organisations are adjusting their strategy
In the UK, the National Health System (NHS) is a major factor of change in that it places engagement and responsibility of the population in their own health and care at the centre of its policy. This is focusing the transformation of the healthcare landscape on cost-effective, positive patient outcomes. Translational research organisations are responding by adjusting their strategies to align with the NHS, to contribute to delivering better patient outcomes, faster. Traditionally, the role of translational research is to increase the volume of basic scientific discovery that goes into clinical research and hopefully, become real clinical innovation. This is because historically, there is a waste of basic scientific learning that goes into clinical research, because of lack of focus and funding, amongst other factors.
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years. Blue Latitude Health
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust. Blue Latitude Health
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid. Blue Latitude Health
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients? Blue Latitude Health
Our creative approach at Fishawack Health is Affective Creativity. Creative crafted to make deep, motivating connections with our target audience. We tap into psychology and combine that with creative craft and expertise and to deliver powerful, engaging work on a conscious as well as a subconscious level. Blue Latitude Health